{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:25:46Z","timestamp":1771669546836,"version":"3.50.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,12,15]]},"DOI":"10.2169\/internalmedicine.6938-20","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T22:08:47Z","timestamp":1625263727000},"page":"3995-3998","source":"Crossref","is-referenced-by-count":4,"title":["Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease"],"prefix":"10.2169","volume":"60","author":[{"given":"Akira","family":"Arakawa","sequence":"first","affiliation":[{"name":"Department of Neurology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritada","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, NTT Medical Center Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79: 685-699, 2020."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367: 2385-2395, 2012.","DOI":"10.1056\/NEJMoa1112802"},{"key":"3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56.001k13_56_61","volume":"95","author":"N Nishimoto","year":"2000","unstructured":"3. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman&apos;s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56-61, 2000.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jbspin.2018.01.002","volume":"85","author":"P Richeb\u00e9","year":"2018","unstructured":"4. Richeb\u00e9 P, Bailly F, Mariani LL, Pena PS, Pedespan JM, Fautrel B. Report of two cases of tocilizumab induced recurrent meningitis or meningoencephalitis. Joint Bone Spine 85: 643-644, 2018.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Garcia T, Dafer R, Hocker S, Schneck M, Barton K, Biller J. Recurrent strokes in two patients with POEMS syndrome and Castleman&apos;s disease. J Stroke Cerebrovasc Dis 16: 278-284, 2007.","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.08.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tanaka J, Fujita A, Hosoda K, Kohmura E. Cerebral angiitis associated with subarachnoid hemorrhage in Castleman&apos;s disease: report of two cases. BMC Neurol 16: 60, 2016.","DOI":"10.1186\/s12883-016-0585-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med 159: 1185-1194, 1999.","DOI":"10.1001\/archinte.159.11.1185"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J 98: 564-566, 2005.","DOI":"10.1097\/01.SMJ.0000155499.21189.75"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rivas-Rodr\u00edguez R, Romero-Alonso MM, Gabella-Bazarot E, S\u00e1nchez-G\u00f3mez E. Efalizumab-induced aseptic meningitis. Farm Hosp 31: 70-71, 2007.","DOI":"10.1016\/S1130-6343(07)75714-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mor\u00eds G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis revisited. JAMA Intern Med 174: 1511-1512, 2014.","DOI":"10.1001\/jamainternmed.2014.2918"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hiraga A, Kuwabara S. Meningitis-retention syndrome: Clinical features, frequency and prognosis. J Neurol Sci 390: 261-264, 2018.","DOI":"10.1016\/j.jns.2018.05.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takahashi O, Sakakibara R, Kishi M, et al. Herbal medicine-induced meningitis-retention syndrome. Intern Med 49: 1813-1816, 2010.","DOI":"10.2169\/internalmedicine.49.3331"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124: 188-195, 2014.","DOI":"10.1182\/blood-2014-05-552729"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_6938-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T03:18:35Z","timestamp":1639797515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/24\/60_6938-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":14,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6938-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"6938-20"}}